P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI

Detalles Bibliográficos
Autores principales: Mateos, M, Szarejko, M, Bila, J, Schjesvold, F, Spicka, I, Maisnar, V, Jurczyszyn, A, Grudeva-Popova, Z, Hajek, R, Usenko, G, Thuresson, M, Norin, S, Jarefors, S, Richardson, P, Pour, L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Poster
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171816/
http://dx.doi.org/10.1097/01.HS9.0000936264.13828.1f

Ejemplares similares

Ejemplares similares